CA2302383A1 - A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist - Google Patents

A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist Download PDF

Info

Publication number
CA2302383A1
CA2302383A1 CA002302383A CA2302383A CA2302383A1 CA 2302383 A1 CA2302383 A1 CA 2302383A1 CA 002302383 A CA002302383 A CA 002302383A CA 2302383 A CA2302383 A CA 2302383A CA 2302383 A1 CA2302383 A1 CA 2302383A1
Authority
CA
Canada
Prior art keywords
methylpiperazin
dihydro
tetrahydro
benzopyran
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002302383A
Other languages
English (en)
French (fr)
Inventor
Seth-Olov Thorberg
Stefan Berg
Svante Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2302383A1 publication Critical patent/CA2302383A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002302383A 1997-09-18 1998-09-09 A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist Abandoned CA2302383A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9703374A SE9703374D0 (sv) 1997-09-18 1997-09-18 A new combination
SE9703374-0 1997-09-18
PCT/SE1998/001600 WO1999013876A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
CA2302383A1 true CA2302383A1 (en) 1999-03-25

Family

ID=20408294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002302383A Abandoned CA2302383A1 (en) 1997-09-18 1998-09-09 A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist

Country Status (29)

Country Link
US (1) US6159972A (cg-RX-API-DMAC10.html)
EP (1) EP1021183B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516717A (cg-RX-API-DMAC10.html)
KR (1) KR20010024075A (cg-RX-API-DMAC10.html)
CN (1) CN1182847C (cg-RX-API-DMAC10.html)
AR (1) AR015447A1 (cg-RX-API-DMAC10.html)
AT (1) ATE261728T1 (cg-RX-API-DMAC10.html)
AU (1) AU752718B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812234A (cg-RX-API-DMAC10.html)
CA (1) CA2302383A1 (cg-RX-API-DMAC10.html)
DE (1) DE69822490T2 (cg-RX-API-DMAC10.html)
DK (1) DK1021183T3 (cg-RX-API-DMAC10.html)
EE (1) EE04142B1 (cg-RX-API-DMAC10.html)
ES (1) ES2216307T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100401A3 (cg-RX-API-DMAC10.html)
IL (1) IL134774A0 (cg-RX-API-DMAC10.html)
IS (1) IS5408A (cg-RX-API-DMAC10.html)
MY (1) MY116281A (cg-RX-API-DMAC10.html)
NO (1) NO20001398L (cg-RX-API-DMAC10.html)
NZ (1) NZ503174A (cg-RX-API-DMAC10.html)
PL (1) PL339370A1 (cg-RX-API-DMAC10.html)
PT (1) PT1021183E (cg-RX-API-DMAC10.html)
RU (1) RU2215528C2 (cg-RX-API-DMAC10.html)
SE (1) SE9703374D0 (cg-RX-API-DMAC10.html)
SK (1) SK2842000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000734T2 (cg-RX-API-DMAC10.html)
TW (1) TW568786B (cg-RX-API-DMAC10.html)
WO (1) WO1999013876A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987810B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
USD969018S1 (en) 2021-06-28 2022-11-08 Koninklijke Asscher Diamant Maatschappij B.V. Rose pear diamond article

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA90673B (en) * 1989-02-02 1990-10-31 Yamanouchi Pharma Co Ltd Tetrahydrobenzimidazole derivatives
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
FI961247A0 (fi) * 1996-03-18 1996-03-18 Finnish Peroxides Ab Oy Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SK2842000A3 (en) 2000-09-12
AR015447A1 (es) 2001-05-02
AU752718B2 (en) 2002-09-26
EP1021183B1 (en) 2004-03-17
IL134774A0 (en) 2001-04-30
TR200000734T2 (tr) 2000-11-21
MY116281A (en) 2003-12-31
NO20001398D0 (no) 2000-03-17
ZA987810B (en) 1999-02-18
PT1021183E (pt) 2004-07-30
DK1021183T3 (da) 2004-07-05
CN1182847C (zh) 2005-01-05
RU2215528C2 (ru) 2003-11-10
WO1999013876A1 (en) 1999-03-25
DE69822490T2 (de) 2005-03-03
CN1279609A (zh) 2001-01-10
TW568786B (en) 2004-01-01
US6159972A (en) 2000-12-12
SE9703374D0 (sv) 1997-09-18
HUP0100401A2 (hu) 2002-01-28
ES2216307T3 (es) 2004-10-16
NO20001398L (no) 2000-04-04
HK1032740A1 (en) 2001-08-03
PL339370A1 (en) 2000-12-18
AU9192998A (en) 1999-04-05
NZ503174A (en) 2002-03-01
BR9812234A (pt) 2000-07-18
DE69822490D1 (de) 2004-04-22
IS5408A (is) 2000-03-15
EE04142B1 (et) 2003-10-15
JP2001516717A (ja) 2001-10-02
HUP0100401A3 (en) 2003-01-28
ATE261728T1 (de) 2004-04-15
EE200000143A (et) 2001-02-15
KR20010024075A (ko) 2001-03-26
EP1021183A1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
EP1014985B1 (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
EP1000048B1 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
EP1014986B1 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST
US6670359B2 (en) Substituted chroman derivatives
EP1025094A1 (en) Substituted indan derivatives
EP1021183B1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
US6291458B1 (en) Morpholinobenzamide salts
HK1032740B (en) A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist
HK1032739B (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
MXPA00002623A (en) A combination of a selective 5-ht1a
MXPA00002612A (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued